Physician profile
Samuel Yoselevitz
NPI 1336279884
$6,399.25
in general payments reported to CMS, 2019-2025
31 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $371 · 2021: $622 · 2022: $1,199 · 2023: $1,225 · 2024: $1,378 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,716 · Education: $22.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,715.53 |
| Education | $22.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,870.28 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $742.30 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $738.81 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $437.70 | 2019-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $275.00 | 2022-2025 | Dupixent |
| Celgene Corporation | $255.34 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $221.03 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $216.14 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $202.31 | 2019-2024 | Ocaliva |
| Pfizer INC. | $142.89 | 2020-2025 | |
| Boston Scientific Corporation | $125.63 | 2022-2025 | Orcapod |
| Nestle Healthcare Nutrition INC. | $119.40 | 2021-2023 | |
| Daiichi Sankyo INC. | $118.35 | 2021-2025 | Injectafer |
| Ambu INC. | $108.44 | 2020 | |
| Ironwood Pharmaceuticals, INC | $104.46 | 2020-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $99.49 | 2019 | |
| Ferring Pharmaceuticals INC. | $96.40 | 2021-2025 | Rebyota |
| Qol Medical, LLC | $78.46 | 2024-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $65.78 | 2021-2025 | |
| Celltrion USA INC. | $61.24 | 2024-2025 | Vegzelma, Zymfentra |
| Genzyme Corporation | $52.55 | 2024 | |
| Organon LLC | $46.86 | 2022-2023 | Renflexis |
| Madrigal Pharmaceuticals | $43.47 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $39.85 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $32.71 | 2022 | |
| Alnylam Pharmaceuticals INC. | $32.53 | 2025 | Givlaari |
| Novo Nordisk INC | $17.51 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $15.97 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.56 | 2023 | Cyltezo |
| Olympus America INC. | $13.53 | 2025 | Visiglide |
| Intra-Sana Laboratories | $10.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Yoselevitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.